Sponsor/Principal Investigator: John Halpern, M.D. Location: McLean Hospital, Harvard Medical School, Belmont, MA (USA) Dr. Halpern is the Sponsor/Investigator. In his FDA IND application, he cross-referenced …
On February 15, 2011, the journal Addiction published online the results of a neuroscience study finding no evidence of impaired cognitive performance in users of Ecstasy, the street name for the chemical …
Harvard MDMA-Cancer/Anxiety Study Update: A study that originated with MAPS, but that is now funded and managed independent of MAPS has had several important updates. The project offers MDMA-assisted psychotherapy …
The MDMA arrived on-site today at Harvard’s McLean Hospital for Dr. John Halpern’s MAPS-initiated study evaluating MDMA-assisted psychotherapy for subjects with advanced-stage cancer suffering …
The Norwegian Research Council website recently posted “Ecstasy: Historien Starter” (article in PDF format) (English translation “Ecstasy; The History Begins”), an article by Pål-Ørjan …
In some fantastic news, philanthropist Peter Lewis has agreed to donate $250,000 directly to Harvard Medical School-affiliated McLean Hospital to fund the costs of Dr. John Halpern’s study of MDMA-assisted …
The DEA has, after over one year, issued a license for Dr. John Halpern’s study of MDMA-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer. The final regulatory …
A DEA Field Investigator came to McLean Hospital to test the alarms on the safes at the Pharmacy, where the roughly 4 grams of MDMA will be stored for the MAPS-sponsored MDMA/cancer anxiety study. Everything …
Today the Drug Enforcement Administration will visit Dr. John Halpern of Harvard Medical School’s McLean Hospital as a routine procedure before issuing his Schedule I license. Once Dr. Halpern has …
ABC News February 23, 2005; Aired 6:30 WORLD NEWS TONIGHT WITH PETER JENNINGS PETER JENNINGS, ABC NEWS commercial break graphics: ecstasy tests PETER JENNINGS (Off Camera) Interesting medical news today, …
Dr. John Halpern submitted his application today to DEA for a Schedule I license, the final regulatory approval required before we can begin the MDMA/cancer anxiety study. Dr. Halpern has already received …
Dr. John Halpern is the guest on C-SPAN’s Washington Journal for a live, half-hour national call-in show focused on Dr. Halpern’s MAPS-sponsored study of MDMA-assisted psychotherapy in subjects …
